Mechanism and regulation of protein kinase functions in HSV nuclear egress
HSV核出口中蛋白激酶功能的机制和调控
基本信息
- 批准号:10088400
- 负责人:
- 金额:$ 19.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-01-24 至 2022-12-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAntigen PresentationAntiviral TherapyApoptosisApoptoticCapsidCell NucleusCellsCytoplasmEventGoldGrowthHerpesviridaeHerpesviridae InfectionsImmune systemInfectionMediatingMolecular BiologyNuclearPathogenesisPhosphorylationPhosphotransferasesProtein KinaseProtein Synthesis InhibitionProteomicsPublishingRegulationReportingSimplexvirusStimulusTestingViralViral ProteinsVirusbasegenetic approachinterestlocus ceruleus structuretool
项目摘要
Alphaherpesviruses encode two proteins kinases that are critical regulators of pathogenesis, pUS3 and pUL13. pUS3 has multiple functions in infection including facilitation of nuclear egress, protection from apoptosis, promotion of viral protein synthesis, and inhibition of antigen presentation to the immune system. The regulation of the activity of pUS3 is, therefore, of great interest, both as a tool for understanding the molecular biology of herpesvirus infections, and as an avenue for exploring antiviral therapies based on inhibition of its various activities. pUS3 kinase activity has been reported to be regulated both by autophosphorylation and by phosphorylation by another herpesvirus-encoded kinase, pUL13. Intriguingly, regulation of pUS3 activity by pUL13 appears to affect some pUS3 functions, but not others. Specifically, it appears to be necessary for at least some of the activities of pUS3 in egress of virus capsids from the nucleus, but not for protection of infected cells from some pro-apoptotic stimuli (). These observations highlight two very significant gaps in our understanding of the interaction between pUL13 and pUS3. First, it is unclear which pUS3 functions are regulated by pUL13, and what distinguished UL13-dependent from UL13-independent functions. We propose the simple hypothesis that phosphorylation of pUS3 by pUL13 specifically regulates its nuclear functions by regulating its access to the nucleus. Second, the mechanism and functional significance of pUL13 regulation of pUS3 is unclear. It is known that pUL13 phosphorylates pUS3, but it is not clear whether this phosphorylation is necessary for pUL13 regulation of pUS3. A recently published proteomic analysis of HSV infected cells suggests that pUL13 phosphorylates pUS3 at S139. We will use a genetic approach to test the hypothesis that S139 is the critical residue for regulation of pUS3 by pUL13, and then to test the significance of S139 phosphorylation for viral growth and spread.
甲疱疹病毒编码两种蛋白激酶,pUS3和pUL13是发病机制的关键调节因子。pUS3在感染中具有多种功能,包括促进核出口、防止细胞凋亡、促进病毒蛋白合成和抑制抗原向免疫系统的递呈。因此,对pUS3活性的调控是非常有趣的,它既是理解疱疹病毒感染分子生物学的工具,也是探索基于抑制其各种活性的抗病毒治疗的途径。据报道,pUS3激酶活性受自磷酸化和另一种疱疹病毒编码的激酶pUL13的磷酸化调节。有趣的是,pUL13对pUS3活性的调节似乎会影响pUS3的一些功能,但不会影响其他功能。具体来说,在病毒衣壳从细胞核流出的过程中,pUS3的至少部分活性似乎是必需的,但在保护受感染细胞免受某些促凋亡刺激方面则不是必需的()。这些观察结果突出了我们对pUL13和pUS3之间相互作用的理解中的两个非常重要的空白。首先,目前尚不清楚pUL13调节哪些pUS3功能,以及区分ul13依赖性和ul13非依赖性功能的原因。我们提出了一个简单的假设,即pUL13对pUS3的磷酸化通过调节其进入细胞核来特异性地调节其核功能。其次,pUL13调控pUS3的机制和功能意义尚不清楚。已知pUL13磷酸化pUS3,但不清楚这种磷酸化对于pUL13调控pUS3是否必要。最近发表的一项HSV感染细胞的蛋白质组学分析表明,pUL13在S139位点磷酸化pUS3。我们将使用遗传学方法验证S139是pUL13调控pUS3的关键残基的假设,然后验证S139磷酸化对病毒生长和传播的意义。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The universal suppressor mutation restores membrane budding defects in the HSV-1 nuclear egress complex by stabilizing the oligomeric lattice.
- DOI:10.1371/journal.ppat.1011936
- 发表时间:2024-01
- 期刊:
- 影响因子:6.7
- 作者:
- 通讯作者:
Herpesvirus Nuclear Egress across the Outer Nuclear Membrane.
疱疹病毒核流横跨外核膜。
- DOI:10.3390/v13122356
- 发表时间:2021-11-24
- 期刊:
- 影响因子:0
- 作者:Roller RJ;Johnson DC
- 通讯作者:Johnson DC
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD J ROLLER其他文献
RICHARD J ROLLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD J ROLLER', 18)}}的其他基金
HSV/VZV chimeric viruses for identifying critical virus herpesvirus assembly interactions
HSV/VZV 嵌合病毒用于识别关键病毒疱疹病毒组装相互作用
- 批准号:
10442813 - 财政年份:2022
- 资助金额:
$ 19.31万 - 项目类别:
HSV/VZV chimeric viruses for identifying critical virus herpesvirus assembly interactions
HSV/VZV 嵌合病毒用于识别关键病毒疱疹病毒组装相互作用
- 批准号:
10556366 - 财政年份:2022
- 资助金额:
$ 19.31万 - 项目类别:
Characterization of the herpes simplex virus cytoplasmic assembly center in neuronal cells
神经元细胞中单纯疱疹病毒细胞质组装中心的表征
- 批准号:
10038761 - 财政年份:2020
- 资助金额:
$ 19.31万 - 项目类别:
Characterization of the herpes simplex virus cytoplasmic assembly center in neuronal cells
神经元细胞中单纯疱疹病毒细胞质组装中心的表征
- 批准号:
10170254 - 财政年份:2020
- 资助金额:
$ 19.31万 - 项目类别:
TorsinA and Nuclear Envelope Function in HSV Infection
TorsinA 和核膜在 HSV 感染中的功能
- 批准号:
8280198 - 财政年份:2012
- 资助金额:
$ 19.31万 - 项目类别:
Virus and Host Factors in HSV Cell-Cell Spread
HSV 细胞间传播中的病毒和宿主因素
- 批准号:
8532474 - 财政年份:2012
- 资助金额:
$ 19.31万 - 项目类别:
TorsinA and Nuclear Envelope Function in HSV Infection
TorsinA 和核膜在 HSV 感染中的功能
- 批准号:
8424221 - 财政年份:2012
- 资助金额:
$ 19.31万 - 项目类别:
相似海外基金
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 19.31万 - 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
- 批准号:
10734324 - 财政年份:2023
- 资助金额:
$ 19.31万 - 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 19.31万 - 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
- 批准号:
23K04971 - 财政年份:2023
- 资助金额:
$ 19.31万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
- 批准号:
2885451 - 财政年份:2023
- 资助金额:
$ 19.31万 - 项目类别:
Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
- 批准号:
10385926 - 财政年份:2022
- 资助金额:
$ 19.31万 - 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
- 批准号:
10509043 - 财政年份:2022
- 资助金额:
$ 19.31万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10704008 - 财政年份:2022
- 资助金额:
$ 19.31万 - 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
- 批准号:
10818273 - 财政年份:2022
- 资助金额:
$ 19.31万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10349397 - 财政年份:2022
- 资助金额:
$ 19.31万 - 项目类别: